top of page

Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use

Publication number
US11096969B2

Assignee

LYMPHOGENIX LTD

Application Domain

Pharmaceutical delivery mechanism

Unknown materials

Cardiovascular disorder

Publication Date

24 Aug 2021

Patent Value

$ 3,100,000

Abstract

The present invention aims to provide a method which has not been established yet and which is useful for achieving long-term and fundamental cure of a necrotic cardiac tissue region to allow recovery of functionality of the heart.
The present invention provides an injectable composition for treatment of a cardiac disease, the composition comprising fibroblasts, wherein the fibroblasts contain CD106-positive fibroblasts, preferably contain CD90-positive fibroblasts, and the fibroblasts do not form colonies.

Technical Problem Summary

Current treatments for cardiac diseases, such as heart failure due to myocardial infarction or cardiomyopathy, lack effective methods for long-term recovery of cardiac function, and existing regenerative medicine approaches have not shown significant long-term improvements in heart function.

Benefit Summary

The administration of CD106-positive fibroblasts leads to improved cardiac function, as evidenced by increased left ventricular ejection fraction and fractional shortening, and significant reduction in collagenous fibrotic infarct areas, indicating effective treatment of cardiac diseases.

Together, we'll go furtner 

for a view yet to be seen.

early stage technology management

© 2025 Biospire Japan Ltd.

bottom of page